FXI抑制剂包括反义寡核苷酸（ASOs)[18]、单克隆抗体、适体和小

FXI抑制剂包括反义寡核苷酸（ASOs)[18]、单克隆抗体、适体和小分子。IONIS-416858是一个针对FXI198的ASO，目前正在临床评估。BMS-986177是一种小分子口服FXIa抑制剂，在I期研究中耐受性良好，目前正在临床II期。AB023（xisomab）是人源化的14E11，一种结合到FXI的apple2结构域并抑制FXIIa介导的FXI激活而不是凝血酶介导的FXI激活的抗体，目前正在临床II期。(4) FXII抑制剂FXII抑制剂是3F7[19]，一种完全人源化的单克隆抗体。3F7在兔ECMO模型中对血栓形成的抑制程度与肝素相同。但FXII在人类血栓形成中的作用还需要进一步研究

0/5000

源语言: -

目标语言: -

结果 (英语) 1: [复制]

复制成功！

FXI inhibitors include antisense oligonucleotides (ASOs) [18], monoclonal antibodies, aptamers, and small molecules. IONIS-416858 is an ASO for FXI198 and is currently undergoing clinical evaluation. BMS-986177 is a small molecule oral FXIa inhibitor, well tolerated in phase I studies and currently in clinical phase II. AB023 (xisomab) is a humanized 14E11, an antibody that binds to the apple2 domain of FXI and inhibits FXIIa-mediated FXI activation rather than thrombin-mediated FXI activation. It is currently in clinical phase II. (4) FXII inhibitor FXII inhibitor is 3F7 [19], a fully humanized monoclonal antibody. 3F7 inhibited thrombosis to the same extent as heparin in the rabbit ECMO model. But the role of FXII in human thrombosis needs further study

正在翻译中..

结果 (英语) 2:[复制]

复制成功！

FXI inhibitors include antonymolinucleic acid (ASOs), monoclonal antibodies, adaptors, and small molecules. IONIS-416858 is an ASO for FXI198 and is currently being clinically evaluated. BMS-986177 is a small molecule oral FXIa inhibitor that is well tolerated in Phase I studies and is currently in clinical phase II. AB023 (xisomab) is a humanized 14E11, an antibody that binds to the Apple2 domain of FXI and inhibits FXI activation instead of coagulation enzyme-mediated FXI activation, and is currently in clinical phase II. (4) FXII inhibitors The FXII inhibitor is 3F7, a completely human-derived monoclonal antibody. 3F7 inhibited thrombosis in the rabbit ECMO model to the same degree as heparin. But the role of FXII in human thrombosis needs further research.

正在翻译中..

结果 (英语) 3:[复制]

复制成功！

FXI inhibitors include antisense oligonucleotides (ASOs) [18], monoclonal antibodies, aptamers and small molecules. Ionis-416858 is an ASO for fxi198 and is currently under clinical evaluation. Bms-986177 is a small molecule oral fxia inhibitor, which is well tolerated in phase I study and is currently in clinical phase II. Ab023 (xisomab) is a humanized 14e11, an antibody that binds to the apple 2 domain of FXI and inhibits the FXI activation mediated by FXIIa rather than the FXI activation mediated by thrombin. It is currently in clinical phase II. (4) FXII inhibitor FXII inhibitor is 3f7 [19], a completely humanized monoclonal antibody. The inhibition of 3f7 on thrombosis in ECMO model was the same as that of heparin. However, the role of FXII in human thrombosis needs further study

正在翻译中..

其它语言

本翻译工具支持: 世界语, 丹麦语, 乌克兰语, 乌兹别克语, 乌尔都语, 亚美尼亚语, 伊博语, 俄语, 保加利亚语, 信德语, 修纳语, 僧伽罗语, 克林贡语, 克罗地亚语, 冰岛语, 加利西亚语, 加泰罗尼亚语, 匈牙利语, 南非祖鲁语, 南非科萨语, 卡纳达语, 卢旺达语, 卢森堡语, 印地语, 印尼巽他语, 印尼爪哇语, 印尼语, 古吉拉特语, 吉尔吉斯语, 哈萨克语, 土库曼语, 土耳其语, 塔吉克语, 塞尔维亚语, 塞索托语, 夏威夷语, 奥利亚语, 威尔士语, 孟加拉语, 宿务语, 尼泊尔语, 巴斯克语, 布尔语(南非荷兰语), 希伯来语, 希腊语, 库尔德语, 弗里西语, 德语, 意大利语, 意第绪语, 拉丁语, 拉脱维亚语, 挪威语, 捷克语, 斯洛伐克语, 斯洛文尼亚语, 斯瓦希里语, 旁遮普语, 日语, 普什图语, 格鲁吉亚语, 毛利语, 法语, 波兰语, 波斯尼亚语, 波斯语, 泰卢固语, 泰米尔语, 泰语, 海地克里奥尔语, 爱尔兰语, 爱沙尼亚语, 瑞典语, 白俄罗斯语, 科西嘉语, 立陶宛语, 简体中文, 索马里语, 繁体中文, 约鲁巴语, 维吾尔语, 缅甸语, 罗马尼亚语, 老挝语, 自动识别, 芬兰语, 苏格兰盖尔语, 苗语, 英语, 荷兰语, 菲律宾语, 萨摩亚语, 葡萄牙语, 蒙古语, 西班牙语, 豪萨语, 越南语, 阿塞拜疆语, 阿姆哈拉语, 阿尔巴尼亚语, 阿拉伯语, 鞑靼语, 韩语, 马其顿语, 马尔加什语, 马拉地语, 马拉雅拉姆语, 马来语, 马耳他语, 高棉语, 齐切瓦语, 等语言的翻译.